{
  "docId": "019de075-746f-7643-8ae7-19646171e75b",
  "docSlug": "e49fd8f0d5e7ac656caa3720c9a74f92",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 28,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "appendix_disclosure",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide uses a bulleted list to present key safety outcomes, including lack of serious adverse events and specific laboratory findings.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-746f-7643-8ae7-19646171e75b/15",
  "deckHref": "/decks/019de075-746f-7643-8ae7-19646171e75b",
  "deckJsonHref": "/decks/019de075-746f-7643-8ae7-19646171e75b.json",
  "deckAnchorHref": "/decks/019de075-746f-7643-8ae7-19646171e75b#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.85,
        "x": 0.076,
        "y": 0.238
      },
      "kind": "list",
      "text": "Imdusiran is generally safe and well-tolerated after repeat dosing for up to 48 weeks; No treatment-related SAEs or discontinuations due to AEs; No treatment-related Grade 3 or 4 AEs; No treatment-related Grade 3 or 4 laboratory abnormalities; Injection site AEs were all Grade 1 (erythema, pain, bruising); No clinically meaningful changes in ECGs or vital signs; After NA treatment discontinuation, no ALT flares have been observed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "528ab7ab-6032-4336-aba6-ac578e96ccfd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.24,
        "x": 0.144,
        "y": 0.948
      },
      "kind": "source-note",
      "text": "SAE: Serious Adverse Event | AE: Adverse Event",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3dceec58-1c2c-42a6-8c6d-ca2c0ca5b232",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.064,
        "w": 0.498,
        "x": 0.076,
        "y": 0.068
      },
      "kind": "title",
      "text": "AB-729-001 Safety Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1237e7e0-62c4-4096-be8a-71259c120a26",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 9,
      "beatId": "8558af21-b173-40d9-bee7-cbb86e4f3ca4",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents Arbutus Biopharma's pipeline, including Imdusiran, AB-161, and AB-101, as a promising approach to treating HBV",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 9,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "cf0f4444-bb37-4efd-b316-e8da602c5aea",
      "evidence": "The deck presents data and results from clinical trials for Imdusiran and other pipeline assets",
      "position": 1,
      "objective": "Showcase Arbutus Biopharma's pipeline as a solution to the HBV problem",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}